NCT06083870View on ClinicalTrials.gov

An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
DRUG

Oba01

Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle

Trial Locations (1)

200030

RECRUITING

Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

Lu Shun

OTHER